A new clinical study out of Poland is adding to the growing interest in cannabis-based skincare. Researchers found that a topical ointment containing CBD and CBG—two non-intoxicating cannabinoids—significantly improved symptoms of atopic dermatitis, more commonly known as eczema.
While it’s a small study, the results were promising: participants saw reduced itching, better skin hydration, and even full remission in some cases.
Key Takeaways
- Researchers studied an ointment with 30% CBD and 5% CBG on adults with eczema.
- After eight weeks, participants reported less itching, better hydration, and in some cases, total symptom relief.
- Skin health markers like water loss and sebum levels improved across the board.
- No significant side effects were reported.
- The study calls for larger trials but supports CBD and CBG’s anti-inflammatory benefits.
Details of the Study
The research, published in Clinical, Cosmetic and Investigational Dermatology, involved nine adult participants with mild-to-moderate eczema. Over the course of eight weeks, they applied a cannabinoid-rich ointment daily.
The formulation contained 30% cannabidiol (CBD) and 5% cannabigerol (CBG)—both derived from hemp. These compounds are already known for their anti-inflammatory and antioxidant properties, making them increasingly popular in topical products for pain, redness, and irritation.
What stood out in this study was the extent of improvement. Researchers noted normalized skin hydration, reduced transepidermal water loss, and better sebum regulation—all key factors in managing eczema.
Visible Improvements and Zero Side Effects
Along with measured skin improvements, participants self-reported less itching, reduced redness, and smoother texture. A few even experienced complete remission of visible symptoms.
Importantly, there were no adverse effects recorded during the trial, which is especially relevant for people seeking alternatives to steroid-based creams or pharmaceutical treatments.
Though the sample size was small, the safety profile and visible progress make a strong case for further investigation into CBD and CBG for eczema relief.
Why It Matters
Atopic dermatitis affects over 30 million people in the U.S. alone. While treatment options exist, many come with side effects or limited effectiveness. As consumer interest in cannabis-infused wellness grows, products that combine cannabinoids like CBD and CBG could offer a gentler option for chronic skin conditions.
However, researchers emphasized the need for larger studies to confirm these results—and to better understand how different cannabinoid combinations interact with various skin types and conditions.
Conclusion
While more data is needed, this study adds to a growing body of research pointing toward the skin-soothing potential of cannabinoids. With no reported side effects and improvements in multiple skin health markers, the findings support what many skincare users and companies have already begun to explore: CBD and CBG may offer real, measurable benefits for eczema sufferers.
If further studies confirm these results, topical cannabis treatments could become a valuable addition to the dermatology toolkit—offering relief without the baggage of traditional prescriptions.
This article is based on publicly available legislative records, court filings, industry reports, and published research as of the publication date. Cannabis laws and regulations change frequently — verify current rules with your state’s regulatory agency.
